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Abstract 
Background: To compare the efficacy of 
Bifidobacterium Infantis with Bifidobacterium 
Bifidum in terms of frequency of necrotizing 
enterocolitis in preterm neonates.  
Methods:  In this comparative cross sectional study 
 652 preterm Neonates with gestational age of less 
than 37 weeks of both genders,  were included. They 
were divided in two groups, one group treated with 
Bifidobacterium Bifidum and other with 
Bifidobacterium Infantis. Both groups were 
managed and monitored for the development of 
clinical evidence of necrotizing enterocolitis during 
hospital stay. 
Results: Comparison of efficacy in both the groups 
showed that 92.94 %( n=303) in Bifidobacterium 
Infantis Group and 96.63 %( n=315) in 
Bifidobacterium Bifidum Group were treated 
effectively, p value was calculated as 0.03 showing a 
significant difference.  
Conclusion: Efficacy of Bifidobacterium Bifidum 
is significantly higher when compared with 
Bifidobacterium Infantis in terms of frequency of 
necrotizing enterocolitis in preterm neonates.   
Key Words: Preterm neonates,  Bifidobacterium 
Infantis, Bifidobacterium Bifidum 
Introduction 
Necrotizing enterocolitis (NEC) is a devastating 
intestinal disease of neonates, and clinical evidence 
suggests the beneficial effect of probiotics in NEC 
prevention. It is a digestive tract emergency in preterm 
neonates.1   It is the varying degree of mucosal or 
transmural necrosis of intestine.2  It affects 15%  of 
very low birth weight preterm neonates.3 Its mortality 
rate is 15-30%.4 Pathogenesis of NEC is multifactorial. 
Main factors increasing its risk are prematurity, enteral 
feeding, colonization by pathogenic microorganisms 
such as E.coli, Klebsiella, Clostridium perfringens, 
Staphylococcus and Rotavirus .5-7 There is no specific 
treatment for NEC.  It is managed with supportive 
treatment. 8 Probiotics are alive organism when given 
in adequate amounts and are beneficial to the host.9 
Probiotics have been recently used in the prevention of 
NEC in preterm neonates. Commonly used probiotics 
for this purpose are Bifidobacterium, Lactobacillus, 
Saccharomyces and Streptococcus thermophillus. 
Their use has shown reduction in the frequency and 
mortality caused by necrotizing enterocolitis.10A  
study conducted at CHA Gangnam Medical Center 
Seoul Korea showed that incidence of NEC without 
probiotics prophylaxis (control group) was 15.8 % and 
after giving probiotics prophylaxis (study group) 
containing  Bifidobacterium  infantis  the incidence 
decreased to 5.5 %.11In another study at University of 
Arizona showed  incidence of NEC without probiotics 
prophylaxis (control group) was  6.45 % and after 
giving  probiotics prophylaxis  (study group) 
containing Bifidobacterium bifidum the incidence 
decreased to 1.84%.12 The aim of present study was to 
compare two groups of probiotics and to establish 
which one is more effective. The effective probiotic can 
be used in preterm neonates for the prevention of NEC 
especially in Neonatal intensive care units.  
 
Patients and Methods  
It was comparative cross sectional study conducted at 
department of Paediatrics Benazir Bhutto Hospital, 
Rawalpindi from November 2014 to April 2015. A total 
number of 652 patients were recruited by consecutive 
(Non probability) sampling. All the Preterm Neonates 
having less than 37 weeks of gestation of both genders 
were included in the study. Preterm neonates in which 
enteral feeding could not be established in first week 
of life, who already have developed necrotizing 
enterocolitis, who were made nothing per oral for 
more than 3 weeks and neonates with other co-morbid 
conditions like birth asphyxia, cyanotic congenital 
heart disease and congenital anal atresia were not 
included. Written informed consent was taken from 
parents. Patients were divided in two groups. Group 
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A(326 patients) and Group B(326 patients). Study 
group (A), receiving probiotic Bifidobacterium Infantis 
and study group (B) receiving probiotic 
Bifidobacterium Bifidum. Probiotic used in the study 
group (A) was Hiflora sachet which is powder for oral 
suspension containing 0.75 x 109 viable cells. Neonate 
in group (A) received probiotic Hiflora ½ TSF or 0.35 
x10 9 viable cells two times a day mixed with milk. 
Probiotic used in control group (B) was Bifedo syrup, 
powder for oral suspension containing viable cells 
1x106. The neonates in study group (B) received 
probiotic Bifedo ½ TSF or 0.5 x 106 viable cells two 
times a day mixed with milk. Both groups were 
managed with same supportive care including 
incubator care, intravenous fluids electrolytes and 
calories, maintenance of thermo neutral environment, 
prevention of hypoxia, acidosis, scheduled touch times 
except for different probiotics in both groups and 
monitored for the development of NEC during 
hospital stay which was diagnosed if 4 of the following 
6 criteria will be there including bradycardia(HR< 
80/min), nasogastric aspiration,  abdominal 
distension, occult blood in stool, thrombocytopenia, 
Pneumatosis Intestinalis on abdominal radiographs. 
Efficacy was determined by the frequency of neonates 
who were given probiotics and prevented from 
developing necrotizing enterocolitis within 14 days of 
hospital stay. Chi square test was applied to compare 
both groups for presence of NEC i.e. efficacy. p-value 
< 0.05 was significant.   
 
Results 
Three hundred and twenty six patients were included 
in Group A and B having mean age 4.08±2.41 and 
4.15±2.44 hours of life respectively.Gender distribution 
showed that 64.11 %(n=209) in    Group-A and 
66.56%(n=217) in Group-B were male while 
35.89%(n=117) in Group-A and 33.44%(n=109) in 
Group-B were females.  Mean gestational age was 
calculated as 33.32+2.41 and 33.46+2.43 weeks in 
Group-A and B respectively ( Table  I). 
Table  1.Comparison of efficacy in both 
groups(n=652) 
Efficacy 
Group-A 
(n=326) 
Group-B 
(n=326) 
No of 
patients 
% 
No  of 
patients 
% 
Yes 303 92.94 315 96.63 
No 23 7.06 11 3.37 
Total 326 100 326 100 
p value=0.03 
Discussion 
In present study comparison of efficacy in both groups 
showed that 92.94%(n=303) in Group-A and 
96.63%(n=315) in Group-B were treated effectively( p= 
0.03; showing sgnificant difference).A recent study has 
shown that incidence of necrotizing enterocolitis 
without probiotics prophylaxis was 15.8% and after 
being treated with probiotics prophylaxis containing 
Bifidobacterium Infantis the incidence decreased to 
5.5%.1 Study by Khailova L et al showed that oral 
administration of B. bifidum reduces severity and 
incidence of NEC. Ileal damage was significantly 
reduced , with p ≤ 0.01 to a median histological score 
of 1.0 as compared 2.0 in the NEC group, and the 
incidence of NEC was markedly decreased to 17% in 
the NEC and B.12 bifidum group compared with the 
NEC group with an incidence of 57%. B.Bifidum 
increases intestinal expression of Toll-like receptors-2 
in NEC. In the intestine, interaction between enteric 
bacteria and the host is mediated in part by Toll-like 
receptors. Appropriate bacterial colonization and the 
activation of these receptors play a key role in the 
pathogenesis of NEC, and administration of probiotics 
increases the expression of these receptors in the 
intestinal epithelium. B. bifidum treatment of NEC not 
only stimulates expression of these receptors in the 
ileal epithelium but also significantly reduces the 
incidence of NEC (from 57 to 17%).12 
Ability of bacteria to cross epithelial cell layers is 
thought to be a crucial step in the cascade of events 
leading to the development of NEC.13,14 Bacterial 
interactions with the premature intestine  play a major 
role in the pathogenesis of NEC. Studies found a 
strong relationship between delay and low 
colonization of commensal florae and proliferation of 
pathogenic florae in the immature gut, predisposing 
preterm infants to develop NEC.13,17 Caplan et al and 
But el et al showed that bifidobacterial 
supplementation resulted in intestinal colonization 
and subsequent reduction in NEC-like lesions.18,19 
Bifidobacteria and lactobacilli have been shown to 
inhibit intestinal colonization of pathogenic 
microorganisms, to produce protective nutrients, and 
to prevent translocation of other bacteria.20  
A study by Riedel CU et al showed that B bifidum not 
only have role in down regulation of pro-
inflammatory cytokines but also have role in  
intervention in inflammatory disorders of the 
gastrointestinal tract. Bifidobacteria acts by locking of 
lipopolysaccharide induced NF-κB activation and 
prevention of amplification of the pro-inflammatory 
signal after exposure to lipopolysaccharide. Ability to 
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inhibit lipopolysaccharide induced NF-κB activation is 
strain-dependent and strains of B. bifidum are 
promising candidates for probiotic intervention in 
inflammatory disorders of the gastrointestinal tract.21 
In another study Lin HC et al incidence of necrotizing 
enterocolitis without probiotics prophylaxis (control 
group) was 6.45% and after giving probiotics 
prophylaxis (study group) containing   
Bifidobacterium Bifidum the incidence decreased to 
1.84%.12 
Wu SF et al observed lower mortality rate in groups 
treated with B Bifidum compared with controls. 
Research evidence indicates that the intestine of 
preterm infants appears far more sensitive to stimuli 
that induce interleukin-8 production .IL-8 is a critical 
component of systemic inflammatory responses in 
neonates resulting from NEC and studies showed that 
probiotics could inhibit IL-8 production.22 
In a study conducted by Repa A et al showed that the 
probiotic B. infantis had no significant impact on the 
overall NEC rates when compared with other 
Bifidobacterium strains in a prospectively followed 
middle European cohort of very low birth weight 
(VLBW) infants. In a subgroup analysis, B. infantis 
significantly reduced NEC in infants fed breast milk 
but was ineffective in infants exclusively fed formula. 
Author concluded that the efficacy of B. Infantis varies 
strongly between centers and was of low efficacy in 
population of VLBW infants. A preventive effect 
against NEC was only present in infants fed breast 
milk in the first 2 week of life, but not in infants 
exclusively fed formula, suggesting that the efficacy of 
probiotics is strongly influenced by feeding practices.23 
Studies reported a decrease in mortality and severity 
of NEC, following probiotics L. acidophilus and B. 
infantis, prophylaxis.24,25, 26  
Conclusion 
Efficacy of Bifidobacterium Bifidum is 
significantly higher when compared with 
Bifidobacterium Infantis in term of frequency of 
necrotizing enterocolitis in preterm neonates. 
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